@import url("/css/styles.css"); @import url("/css/styles-green.css");
Avlar BioVentures
About Avlar
Management
Active Management
Leaders in Life Sciences
Cambridge Cluster
Presentations
Testimonials
Portfolio Companies
Quoted Companies
PAION
Unquoted Companies
Amura Ltd
Crescendo Biologics
CellCentric Ltd
De Novo Pharmaceuticals
ImmunoBiology Ltd
Medical Device Innovation
Proteom
Purely Proteins
Sold Companies
Paradigm Therapeutics
Cozart plc
Sterix Limited
Cambridge Biotechnology L
Sangamo BioSciences
CeNeS
Portfolio News
For Investors
The Funds
Our Investors
Preferred Advisors
Contact Us
How to find us
You are here:
Homepage
>
Preferred Advisors
Quoted Portfolio Companies
PAION
Unquoted Portfolio Companies
Amura Ltd
Crescendo Biologics
CellCentric Ltd
De Novo Pharmaceuticals
ImmunoBiology Ltd
Medical Device Innovation
Proteom
Purely Proteins
Sold Companies
Paradigm Therapeutics
Cozart plc
Sterix Limited
Cambridge Biotechnology L
Sangamo BioSciences
CeNeS
Friday, July 30, 2010
Preferred Advisors
Morrison & Foerster MNP, solicitors
Portfolio News
18 March 2010
Regenerative Medicine Assets Limited - Sale of ICX-TRC
23 February 2010
CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda
26 January 2010
CellCentric epigenetic imprint erasure factor published in Nature
All Portfolio News
News Archive
2004
News Archive
Our Investors
3i
Access Capital Partners
Astellas Venture Capital
Avlar management
BTG
Cambridge University
Coller Capital
European Investment Fund
Lloyds TSB DC
Lexington Partners Inc
Preferred Advisors
Morrison & Foerster MNP
Opportunities
CEOs with relevant experience for start-up / early stage Life Science companies.